Cholesterol ester transfer protein: A therapeutic target in atherosclerosis?

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 8, 2008, Pages 937-948

  Vourvouhaki, Ekaterini ^a   Dedoussis, George V ^a  

^a HAROKOPIO UNIVERSITY   (Greece)

Author keywords

Atherosclerosis; Cardiovascular diseases; CETP; Cholesterol; HDL; LDL; Lipid metabolism; RCT

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ALDOSTERONE; ANACETRAPIB; APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; CETI 1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 0859; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PITAVASTATIN; PLACEBO; PRAVASTATIN; SCAVENGER RECEPTOR BI; SIMVASTATIN; TORCETRAPIB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; GENETIC VARIABILITY; HEART INFARCTION; HEART PROTECTION; HOMEOSTASIS; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID HYDROLYSIS; LIPID METABOLISM; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG DESIGN; HUMANS; MICE; POLYMORPHISM, GENETIC; RABBITS;

EID: 48449096283     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.8.937     Document Type: Review

References (104)

1. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92(5):1355-74
2. Cardiovascular diseases World Health Organisation. web page. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html [Last accessed 20 May 2008]
3. Kannel WB, Sytkowski PA. Atherosclerosis risk factors. Pharmacol Ther 1987;32(3):207-35
4. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62(5):707-14
5. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11-20
6. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23(2):160-7
7. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34(8):1255-74
8. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987;327(6123):632-4
9. Jiang XC, Moulin P, Quinet E, et al. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J Biol Chem 1991;266(7):4631-9
10. Tollefson JH, Faust R, Albers JJ, Chait A. Secretion of a lipid transfer protein by human monocyte-derived macrophages J Biol Chem 1985;260(10):5887-90
11. Ishikawa Y, Ito K, Akasaka Y, et al. The distribution and production of cholesteryl ester transfer protein in the human aortic wall. Atherosclerosis 2001;156(1):29-37
12. Brewer HB Jr, Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease Arterioscler Thromb Vasc Biol 2004;24(10):1755-60
13. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47(3):492-9
14. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000;1529(1-3):245-56
15. Tall AR, Sammett D, Vita GM, et al. Lipoprotein lipase enhances the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from high density lipoproteins to very low density lipoproteins. J Biol Chem 1984;259(15):9587-94
16. Zechner R, Dieplinger H, Steyrer E, et al. In vitro formation of HDL-C-2 from HDL-C-3 and triacylglycerol-rich lipoproteins by the action of lecithin:cholesterol acyltransferase and cholesterol ester transfer protein Biochim Biophys Acta 1987;918(1):27-35
17. Miyazaki A, Nakayama H, Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 2002;12(6):258-62
18. Temel RE, Walzem RL, Banka CL, Williams DL. Apolipoprotein A-I is necessary for the in vivo formation of high density lipoprotein competent for scavenger receptor BI-mediated cholesteryl ester-selective uptake. J Biol Chem 2002;277(29):26565-72
19. Matsuura F, Wang N, Chen W, et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCGI-dependent pathway. J Clin Invest 2006;116(5):1435-42
20. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998;18:297-330
21. Morton RE, Greene DJ. CETP and lipid transfer inhibitor protein are uniquely affected by the negative charge density of the lipid and protein domains of LDL. J Lipid Res 2003;44(12):2287-96
22. Pattnaik NM, Zilversmit DB. Interaction of cholesteryl ester exchange protein with human plasma lipoproteins and phospholipid vesicles. J Biol Chem 1979;254(8):2782-6
23. De Grooth GJ, Klerkx AH, Stroes ES, et al. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45(11):1967-74
24. Bruce C, Tall AR. Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis Curr Opin Lipidol 1995;6(5):306-11
25. Marotti KR, Castle CK, Boyle TP, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364(6432):73-5
26. Plump AS, Masucci-Magoulas L, Bruce C, et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999;19(4):1105-10
27. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene J Clin Invest 1995;96(4):2071-4
28. Van Eck M, Ye D, Hildebrand RB, et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res 2007;100(5):678-85
29. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem 2003;278(26):23699-705
30. Harder C, Lau P, Meng A, et al. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. Arterioscler Thromb Vasc Biol 2007;27(4):858-64
31. Tanigawa H, Miura S, Zhang B, et al. Low-density lipoprotein oxidized to various degrees activates ERK1/2 through Lox-1. Atherosclerosis 2006;188(2):245-50
32. Tchoua U, D'Souza W, Mukhasnedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res 2008;77(4):732-9
33. Ha YC, Barter PJ. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B 1982;71(2):265-9
34. Sugano M, Makino N, Sawada S, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998;273(9):5033-6
35. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20(9):2106-12
36. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406(6792):203-7
37. Huang Z, Inazu A, Nohara A, et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002;103(6):587-94
38. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007;48(6):1263-72
39. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323(18):1234-8
40. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL-C levels. J Clin Invest 1996;97(12):2917-23
41. Curb, JD, Abbott, RD, Rodriguez, BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the eldery. J Lipid Res 2004;45:948-53
42. Klerkx AH, de Grooth GJ, Zwinderman AH, et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004;34(1):21-8
43. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004;110(11):1418-23
44. Savolainen MJ, Hannuksela M, Seppänen S, et al. Increased high-density lipoprotein cholesterol concentration in alcoholics is related to low cholesteryl ester transfer protein activity. Eur J Clin Invest 1990;20(6):593-9
45. Dullaart RP, Hoogenberg K, Dikkeschei BD, van Tol A. Higher plasma lipid transfer protein activities and unfavourable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994;14(10):1581-5
46. Freeman DJ, Griffin BA, Murray E, et al. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest 1993;23(10):630-40
47. Sparks DL, Pritchard PH. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL-C lipid and apoprotein content. J Lipid Res 1989;30(10):1491-8
48. de Grooth GJ, Smilde TJ, Van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia Atherosclerosis 2004;173(2):261-7
49. Tall A, Granot E, Brocia R, et al. Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. J Clin Invest 1987;79(4):1217-25
50. McPherson R, Mann CJ, Tall AR, et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb 1991;11(4):797-804
51. Ordovas JM, Gupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000;20:1323-9
52. Freeman DJ, Griffin BA, Holmes AP, et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors: associations between the Taq I B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994;14:336-44
53. Brousseau ME, O'Connor JJ Jr, Ordovas JM, et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002;22(7):1148-54
54. Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2003;24(20):1833-42
55. Mitchell RJ, Earl L, Williams J, et al. Polymorphisms of the gene coding for the cholesteryl ester transfer protein and plasma lipid levels in Italian and Greek migrants to Australia. Hum Biol 1994;66:13-25
56. Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995;96:1664-71
57. Padmaja N, Ravindra Kumar M, Soya SS, Adithan C. Common variants of Cholesteryl ester transfer protein gene and their association with lipid parameters in healthy volunteers of Tamilian population. Clin Chim Acta 2007;375(1-2):140-6
58. Ayyobi AF, Hill JS, Molhuizen HO, Lear SA. Cholesterol ester transfer protein (CETP) Taq1B polymorphism influences the effect of a standardized cardiac rehabilitation program on lipid risk markers. Atherosclerosis 2005;181(2):363-9
59. Hsieh MC, Chen CC, Wang JY, et al. Cholesteryl ester transfer protein B1B1 genotype is associated with a parental history of cardiovascular diseases in Taiwanese people. Med Princ Pract 2008;17(2):143-8
60. Sandhofer A, Tatarczyk T, Laimer M, et al. The Taq1B-variant in the cholesteryl ester-transfer protein gene and the risk of metabolic syndrome. Obesity (Silver Spring) 2008;16(4):919-22
61. Klerkx AH, Tanck MW, Kastelein JJ, et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003;12(2):111-23
62. Borggreve SE, de Vries R, Dailinga-Thie GM W, et al. The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C→A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity. Biochim Biophys Acta 2008;1781(1-2):10-5
63. Spielmann N, Leon AS, Rao DC, CETP genotypes and HDL-cholesterol phenotypes in the HERITAGE Family Study. Physiol Genomics 2007;31(1):25-31
64. Dachet C, Poirier O, Cambien F, et al. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000;20(2):507-15
65. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. The effect of cholesteryl ester transfer protein -629C→A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab 2005;90(7):4198-204
66. Le Goff W, Guerin M, Petit L, et al. Regulation of human CETP gene ovexpression: role of SP1 and SP3 transcription factors at promoter sites -690, -629, and -37. J Lipid Res 2003;44(7):1322-31
67. Bruce C, Sharp DS, Tall AR. Relationship of HDL-C and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998;39(5):1071-8
68. Corbex M, Poirier O, Fumeron F, et al. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet Epidemiol 2000;19(1):64-80
69. Kakko S, Tamminen M, Kesäniemi YA, Savolainen MJ. R451Q mutation in the cholesteryl ester transfer protein (CETP) gene is associated with high plasma CETP activity. Atherosclerosis 1998;136(2):233-40
70. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003;290(15):2030-40
71. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL-C levels. J Clin Invest 1996;97(12):2917-23
72. Agerholm-Larsen B, Tybjaerg-Hansen A, et al. Common cholesteryl ester transfer protein mutations, decreased HDL-C cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 2000;102(18):2197-203
73. Cazita PM, Barbeiro DF, Moretti AI, et al. Human CETP expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP Shock. Published online 26 May 2008, doi: 10.1097/SHK.0b013e31816e30fd
74. Izem L, Morton RE. Possible role for intracellular cholesteryl ester transfer protein in adipocyte lipid metabolism and storage. J Biol Chem 2007;282(30):21856-65
75. Radeau T, Robb M, Lau P, et al. Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. Atherosclerosis 1998;139(2):369-76
76. Dullaart RP, Sluiter WJ, Dikkeschei LD, et al. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994;24:188-94
77. Hayashibe H, Asayama K, Nakane T, et al. Increased plasma cholesteryl ester transfer activity in obese children. Atherosclerosis 1997;129(1):53-8
78. MacLean PS, Bower JF, Vadlamudi S, et al. Lipoprotein subpopulation distributions in lean, obese, and type 2 diabetic women: a comparison of African and white Americans. Obes Res 2000;8(1):62-70
79. Asayama K, Hayashibe H, Dobashi K, et al. Increased serum cholesteryl ester transfer protein in obese children. Obes Res 2002;10(6):439-46
80. Dedoussis GV, Panagiotakos DB, Louizou E, et al. Cholesteryl ester-transfer protein (CETP) polymorphism and the association of acute coronary syndromes by obesity status in Greek subjects: the CARDIO2000-GENE study. Hum Hered 2007;63(3-4):155-61
81. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7
82. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104(25):3046-51
83. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
84. Kawano M, Nagasaka S, Yagyu H, Ishibashi S. Pitavastatin decreases plasma preβ1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb 2008; 15(1):41-6
85. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004;15(6):659-65
86. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345(22):1583-92
87. Backes JM, Gibson CA. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother 2005;39(3):523-6
88. Shepherd J, Betteridge J, Van Gaal L. European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005;21(5):665-82
89. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258(2):94-114
90. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231(4):360-81
91. Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998;81(7):912-7
92. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341(6):410-8
93. Remick J, Weintraub H, Setton R, et al. Fibrate therapy: an update. Cardiol Rev 2008;16(3):129-41
94. Davidson MH, Maki K, Umporowicz D, et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003;169(1):113-20
95. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT.705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95(9):1085-8
96. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2180-3
97. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004;24(3):387-91
98. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL-C cholesterol. N Engl J Med 2004;350(15):1505-15
99. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356(16):1620-30
100. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370(9582):153-60
101. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356(13):1304-16
102. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370(9603):1882-3
103. Schaefer EJ, Asztalos BF. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol 2007;100(11 A):n25-31
104. Rader DJ. Illuminating HDL-is it still a viable therapeutic target? N Engl J Med 2007;357:2180-83